# Considerations for Carnosine Actions in Biology

**Authors:** Belisa Parmeggiani, Bruna Klippel Ferreira, Patricia Fernanda Schuck, Gustavo Costa Ferreira

PMC · DOI: 10.1007/s11064-026-04735-5 · Neurochemical Research · 2026-03-27

## TL;DR

This paper discusses the various roles and effects of carnosine in biological systems, emphasizing its potential and uncertainties, especially during development.

## Contribution

The paper highlights the need to reconsider carnosine's applications due to its complex and variable biological effects.

## Key findings

- Carnosine affects cell survival, redox homeostasis, and signaling.
- Its effects vary based on factors like concentration, exposure time, and developmental stage.
- Carnosinemia, a disorder involving carnosine accumulation, is linked to neuropsychomotor dysfunction.

## Abstract

Carnosine is a histidinic dipeptide mainly identified for its pH buffering, antioxidant and metal chelating capacities. Several studies have explored the potential benefits of carnosine as a supplement for exercise, as well as an adjuvant treatment in several pathologies; however, roles and impacts of carnosine on most tissues, including the brain, are still under debate, especially in earlier stages of development. There is evidence that carnosine may impact a myriad of physiological parameters. It includes potential roles of carnosine as a modulator of cell survival, redox homeostasis, signaling and metabolism, among other functions. Many variables seem to impact the outcomes of carnosine actions (e.g., carnosine concentrations, length of exposure, target cell/tissue, biological sex, metabolic state, and developmental stage). Considering that the physiology and metabolism of histidine dipeptides change throughout life, impacts of carnosine during development should be carefully considered. This is particularly relevant in light of carnosinemia, an inherited disorder of carnosine catabolism characterized by the accumulation of carnosine and presenting neuropsychomotor dysfunction. Thus, rethinking the applications of carnosine is crucial for realization of the full potential of this promising molecule.

## Linked entities

- **Chemicals:** carnosine (PubChem CID 439224)
- **Diseases:** carnosinemia (MONDO:0008921)

## Full-text entities

- **Genes:** MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, CNDP2 (carnosine dipeptidase 2) [NCBI Gene 55748] {aka CN2, CPGL, HEL-S-13, HsT2298, PEPA}, CNDP1 (carnosine dipeptidase 1) [NCBI Gene 84735] {aka CN1, CPGL2, HsT2308}, SLC15A2 (solute carrier family 15 member 2) [NCBI Gene 6565] {aka PEPT2}, LYPD1 (LY6/PLAUR domain containing 1) [NCBI Gene 116372] {aka LYPDC1, PHTS}, SLC15A4 (solute carrier family 15 member 4) [NCBI Gene 121260] {aka FP12591, PHT1, PTR4}, MAOA (monoamine oxidase A) [NCBI Gene 4128] {aka BRNRS, MAO-A}, CARNS1 (carnosine synthase 1) [NCBI Gene 57571] {aka ATPGD1}, ABAT (4-aminobutyrate aminotransferase) [NCBI Gene 18] {aka GABA-AT, GABAT, NPD009}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, SLC15A3 (solute carrier family 15 member 3) [NCBI Gene 51296] {aka OCTP, PHT2, PTR3, hPHT2}, SLC15A1 (solute carrier family 15 member 1) [NCBI Gene 6564] {aka HPECT1, HPEPT1, PEPT1}
- **Diseases:** paresthesia (MESH:D010292), nausea (MESH:D009325), dementia (MESH:D003704), insulin sensitivity (MESH:D007333), autism spectrum disorder (MESH:D000067877), hypotonia (MESH:D009123), coronary heart disease (MESH:D003327), demyelinating lesions (MESH:D003711), diabetic nephropathy (MESH:D003928), cancer (MESH:D009369), obesity (MESH:D009765), type 2 diabetes (MESH:D003924), diseases (MESH:D004194), epilepsy (MESH:D004827), glioblastoma (MESH:D005909), autosomal recessive inborn error of metabolism (MESH:D008661), upper gastrointestinal cancer (MESH:D005770), neuropsychomotor dysfunction (MESH:D006331), overweight (MESH:D050177), psychomotor and cognitive delay (MESH:D003072), Parkinson's and Alzheimer's diseases (MESH:D010300), psychiatric disorders (MESH:D001523), Alzheimer's (MESH:D000544), neuroinflammation (MESH:D000090862), neurological dysfunction (MESH:D009461), heart failure (MESH:D006333), cardiovascular disorders (MESH:D002318), muscular dystrophy (MESH:D009136), tremors (MESH:D014202), Online Mendelian Inheritance in Man - OMIM #212200 (MESH:D030342), seizures (MESH:D012640), headache (MESH:D006261), Zucker diabetic fatty (MESH:D003920), nervous system diseases (MESH:D009422), Carnosinemia (MESH:C535328), COVID19 (MESH:D000086382)
- **Chemicals:** reactive oxygen species (MESH:D017382), Ca2+ (-), Calcium (MESH:D002118), serotonin (MESH:D012701), 3-nitrotyrosine (MESH:C002744), amino acids (MESH:D000596), dipeptide (MESH:D004151), 8-isoprostane (MESH:C075750), glutathione (MESH:D005978), beta-alanine (MESH:D015091), lactate (MESH:D019344), glutamate (MESH:D018698), hydrogen peroxide (MESH:D006861), histamine (MESH:D006632), oxygen (MESH:D010100), metal (MESH:D008670), MK-801 (MESH:D016291), L-histidine (MESH:D006639), lipid (MESH:D008055), glucose (MESH:D005947), water (MESH:D014867), glycine (MESH:D005998), anserine (MESH:D000861)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Bos taurus (bovine, species) [taxon 9913], Rattus norvegicus (brown rat, species) [taxon 10116], Equus caballus (domestic horse, species) [taxon 9796], Danio rerio (leopard danio, species) [taxon 7955], Homo sapiens (human, species) [taxon 9606], Sus scrofa (pig, species) [taxon 9823]
- **Cell lines:** C2C12 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0188)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13031222/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13031222/full.md

---
Source: https://tomesphere.com/paper/PMC13031222